Market Expansion Opportunity to expand BloodSTOP iX Advanced Hemostat into new regional markets such as West Africa and other underserved regions, leveraging existing partner KITSS Therapeutics to accelerate introduction in Ghana, Liberia, and adjacent markets.

EMS and Surgery Focus Strong sales angle in prehospital EMS, surgical procedures including burn and trauma care, and chronic wound management (diabetic ulcers, decubitus ulcers) where rapid hemostasis and wound healing can reduce complications and hospital stays.

Strategic Partnerships Leverage ongoing KITSS Therapeutics collaboration and potential additional distribution partners to scale reach, supported by the BloodSTOP iX patent and WoundHEAL technology for competitive differentiation.

Online and DTC Readiness Capitalize on BloodSTOP online store presence and e-commerce tooling (Shopify/WooCommerce) to run direct-to-clinic promotions, training modules, and clinician-focused campaigns to drive trials and adoption.

Brand and IP Leverage Position LifeScience PLUS as a technology-led wound care innovator with a focus on advanced hemostasis and moist wound care, using IP and case outcomes to support clinician education, tender bids, and regulatory submissions.